Skip to Main Content

Paper Details

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
Eur Urol Focus
17
2019
ERG, PARTICIPANTS, PATIENT, PCA3, PCPTRC, Prostate Cancer, T2, TMPRSS2, Urinary Prostate Cancer Antigen 3, high-grade cancer, patients, prostate cancer, prostate cancer antigen 3
Author NameAffiliation
Martin GorosUniversity of Texas Health at San Antonio
Martin GorosUniversity of Texas Health at San Antonio
Scott A TomlinsMichigan Center for Translational Pathology, University of Michigan Medical School ann arbor
Ian M ThompsonCHRISTUS Medical Center Hospital
Robin J LeachUniversity of Texas Health at San Antonio
Michael A LissUniversity of Texas Health at San Antonio
  • 1 - 6

Datasets

Release 1.2